Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Anastrozole
Drug ID BADD_D00142
Description Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer.[L8863] Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and acne.[A186865] Aromatase inhibitors, including anastrozole, have become endocrine drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and adverse effect profile as compared to earlier estrogen receptor modulators such as [tamoxifen].[A186877,A186955] Anastrozole was first approved for use in the United States in 1995.[L8863]
Indications and Usage For adjuvant treatment of hormone receptor positive breast cancer , as well as hormonal treatment of advanced breast cancer in post-menopausal women. Has also been used to treat pubertal gynecomastia and McCune-Albright syndrome; however, manufacturer states that efficacy for these indications have not been established.
Marketing Status Prescription; Discontinued
ATC Code L02BG03
DrugBank ID DB01217
KEGG ID D00960
MeSH ID D000077384
PubChem ID 2187
TTD Drug ID D0W0BF
NDC Product Code 63850-6527; 0395-8157; 68554-0026; 0310-0201; 71335-1879; 65129-1119; 16729-035; 68071-1682; 71052-248; 72789-008; 65096-0117; 51991-620; 59651-236; 65072-0702; 63629-5269; 16571-421; 63850-0010; 82393-201; 62135-490; 63187-080; 62559-670; 50090-2453; 58623-0041; 55111-814; 68382-209; 51927-4435; 68001-155; 50090-5002; 65841-743; 76420-004; 50268-075; 0093-7536; 61200-104; 42291-085; 46014-1160; 70518-2484; 73377-120; 69988-0013; 50090-5812; 62756-428; 62157-077; 70934-488; 70518-2420; 60429-286; 68071-5203; 60687-112; 51552-1568; 46014-1009; 38779-2555; 0904-6195; 43063-383; 60440-2921; 53104-7627; 62175-710
Synonyms Anastrozole | 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile) | Anastrazole | Arimidex | ICI D1033 | ZD-1033 | ZD 1033 | Zeneca ZD 1033 | ZD1033
Chemical Information
Molecular Formula C17H19N5
CAS Registry Number 120511-73-1
SMILES CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cardiovascular disorderAdenylate kinase isoenzyme 1P00568Not Available9456245; 10473018; 14623544; 10514021; 10388095; 9556789; 15814851; 14513432; 11850229; 14687601; 15083379
OsteoporosisAdenylate kinase isoenzyme 1P00568Not Available9456245; 10473018; 14623544; 10514021; 10388095; 9556789; 15814851; 14513432; 11850229; 14687601; 15083379
Urogenital disorderAdenylate kinase isoenzyme 1P00568Not Available9456245; 10473018; 14623544; 10514021; 10388095; 9556789; 15814851; 14513432; 11850229; 14687601; 15083379
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Drug intolerance08.06.01.0130.005279%Not Available
Neoplasm recurrence16.16.02.0040.000197%Not Available
Pulmonary toxicity12.03.01.013; 22.01.02.0070.001131%Not Available
Hepatobiliary disease09.01.08.003--Not Available
Vitamin D decreased13.02.05.0060.001886%Not Available
Metastasis16.22.01.0010.000492%Not Available
Nasal disorder22.04.03.0040.001131%Not Available
Renal impairment20.01.03.0100.002640%Not Available
Tooth fracture12.01.09.010; 07.09.05.0080.001508%Not Available
Complex regional pain syndrome17.02.07.010; 12.01.12.0040.000197%Not Available
Osteonecrosis of jaw24.04.05.005; 15.02.04.0100.002263%
Tendon pain15.07.01.0090.000393%Not Available
Organising pneumonia22.01.02.0080.007165%Not Available
Oestrogenic effect05.05.04.004--Not Available
Skin mass23.07.04.0140.000754%Not Available
Acute kidney injury20.01.03.016--
Atypical femur fracture12.04.01.019; 15.08.03.0190.000754%Not Available
Posterior reversible encephalopathy syndrome17.13.02.0070.000197%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.004525%Not Available
Intraductal proliferative breast lesion21.05.01.014; 16.10.01.0060.001508%Not Available
Reversible cerebral vasoconstriction syndrome24.04.06.026; 18.06.01.004; 17.08.02.0140.001131%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.0210.001508%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000590%
Liver function test increased13.03.01.0440.000754%Not Available
Antiphospholipid syndrome18.02.04.002; 10.04.01.009; 01.01.02.016; 24.01.01.0290.002640%Not Available
Biliary cirrhosis primary10.04.09.003; 09.01.04.0070.000754%Not Available
Breast cancer recurrent21.05.01.017; 16.10.01.0090.006034%Not Available
Cartilage injury15.07.03.005; 12.04.03.0070.000197%Not Available
Endometrial cancer metastatic16.12.02.004; 21.07.02.0120.000197%Not Available
Malignant pleural effusion22.05.04.001; 16.32.03.0140.000197%Not Available
The 15th Page    First    Pre   15 16    Next   Last    Total 16 Pages